Ignite Creation Date:
2025-12-24 @ 2:20 PM
Ignite Modification Date:
2026-02-21 @ 9:07 PM
Study NCT ID:
NCT03282695
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-03-04
First Post:
2017-09-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Ozone Therapy in Patients on Waiting List for Surgery Due to Disc Herniation: Prospective, Post-authorization Study
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007405', 'term': 'Intervertebral Disc Displacement'}], 'ancestors': [{'id': 'D013122', 'term': 'Spinal Diseases'}, {'id': 'D001847', 'term': 'Bone Diseases'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D006547', 'term': 'Hernia'}, {'id': 'D020763', 'term': 'Pathological Conditions, Anatomical'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 70}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2018-03-09', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-02', 'completionDateStruct': {'date': '2026-03-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-02-28', 'studyFirstSubmitDate': '2017-09-12', 'studyFirstSubmitQcDate': '2017-09-13', 'lastUpdatePostDateStruct': {'date': '2025-03-04', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2017-09-14', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-12-31', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Direct Hospital Cost for patients included on waiting list for surgery due to disc herniation.', 'timeFrame': '24 months', 'description': 'Euros'}, {'measure': 'Percentage of surgeries finally performed.', 'timeFrame': '24 months', 'description': 'Percentage of surgeries performed after enrollment'}, {'measure': 'Change from Baseline in sciatic pain at 12 months', 'timeFrame': '12 months', 'description': 'Visual Analogic Scale (VAS)'}, {'measure': 'Change from Baseline in sciatic pain at 24 months', 'timeFrame': '24 months', 'description': 'Visual Analogic Scale (VAS)'}], 'secondaryOutcomes': [{'measure': 'Change from Baseline in sciatic pain at 6 months', 'timeFrame': '6 months', 'description': 'Visual Analogic Scale (VAS)'}, {'measure': 'Change from Baseline in lumbar pain at 6 months', 'timeFrame': '6 months', 'description': 'Visual Analogic Scale (VAS)'}, {'measure': 'Change from Baseline in lumbar pain at 12 months', 'timeFrame': '12 months', 'description': 'Visual Analogic Scale (VAS)'}, {'measure': 'Change from Baseline in lumbar pain at 24 months', 'timeFrame': '24 months', 'description': 'Visual Analogic Scale (VAS)'}, {'measure': 'Number of hospital stay days', 'timeFrame': '24 months', 'description': 'Number of hospital stay days'}, {'measure': 'Restriction of everyday activities', 'timeFrame': '24 months', 'description': 'Spanish version of Roland-Morris questionnaire'}, {'measure': 'Quality of life by 12-Item Short Form Survey (SF-12)', 'timeFrame': '24 months', 'description': 'SF-12 questionnaire'}, {'measure': 'Quality of life by the five-level version of the EuroQol five-dimensional (EQ-5D-5L) questionnaire', 'timeFrame': '24 months', 'description': 'EQ-5D-5L questionnaire'}, {'measure': 'Loss of labour productivity', 'timeFrame': '24 months', 'description': 'Off work days (if applicable)'}, {'measure': 'Time to resume normal activity', 'timeFrame': '24 months', 'description': 'Days'}, {'measure': 'Direct sanitary and non-sanitary costs incurred out of hospital.', 'timeFrame': '24 months', 'description': 'Euros'}, {'measure': 'Adverse effects', 'timeFrame': '24 months', 'description': 'Number of serious adverse effects'}, {'measure': 'Time from inclusion on waiting list for surgery to completion of the procedure.', 'timeFrame': '24 months', 'description': 'Days'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Disc Herniation', 'Lumbar Herniated Disc', 'Ozone Therapy'], 'conditions': ['Lumbar Herniated Disc']}, 'referencesModule': {'references': [{'pmid': '16683121', 'type': 'BACKGROUND', 'citation': 'Hansson E, Hansson T. The cost-utility of lumbar disc herniation surgery. Eur Spine J. 2007 Mar;16(3):329-37. doi: 10.1007/s00586-006-0131-y. Epub 2006 May 9.'}, {'pmid': '21289928', 'type': 'BACKGROUND', 'citation': 'Luhmann D, Burkhardt-Hammer T, Borowski C, Raspe H. Minimally invasive surgical procedures for the treatment of lumbar disc herniation. GMS Health Technol Assess. 2005 Nov 15;1:Doc07.'}, {'pmid': '22430658', 'type': 'BACKGROUND', 'citation': 'Magalhaes FN, Dotta L, Sasse A, Teixera MJ, Fonoff ET. Ozone therapy as a treatment for low back pain secondary to herniated disc: a systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2012 Mar-Apr;15(2):E115-29.'}, {'pmid': '19819761', 'type': 'BACKGROUND', 'citation': 'Sherman J, Cauthen J, Schoenberg D, Burns M, Reaven NL, Griffith SL. Economic impact of improving outcomes of lumbar discectomy. Spine J. 2010 Feb;10(2):108-16. doi: 10.1016/j.spinee.2009.08.453. Epub 2009 Oct 12.'}, {'pmid': '18777603', 'type': 'BACKGROUND', 'citation': 'Tosteson AN, Skinner JS, Tosteson TD, Lurie JD, Andersson GB, Berven S, Grove MR, Hanscom B, Blood EA, Weinstein JN. The cost effectiveness of surgical versus nonoperative treatment for lumbar disc herniation over two years: evidence from the Spine Patient Outcomes Research Trial (SPORT). Spine (Phila Pa 1976). 2008 Sep 1;33(19):2108-15. doi: 10.1097/brs.0b013e318182e390.'}], 'seeAlsoLinks': [{'url': 'http://www3.gobiernodecanarias.org/sanidad/scs/content/4c7be1f8-a10e-11e6-a33b-757951c5b2fa/Informe_Ozonoterapia_SESCS%202016.pdf', 'label': 'Report (June 2016) about Ozone therapy in disc herniation, from the Health Technology Assessment (HTA) Unit, Canary Health Service, Spain'}]}, 'descriptionModule': {'briefSummary': 'The main objective of this study is to estimate the cost-effectiveness of ozone therapy in patients on the waiting list for surgery due to disc herniation.', 'detailedDescription': 'A cohort study (patients on the waiting list for surgery due to herniated disc) will be carried out, to which the treatment with ozone will be offered, without giving up the planned surgical intervention.\n\nThe main objective of this prospective, post-authorization follow-up study is to estimate the cost-effectiveness of ozone therapy (compared to standard care) in patients with disc herniation waiting for surgery (by microdiscectomy). Besides utilities of patients with disc herniation on a waiting list for surgery will be estimated, social/economic burden of disc herniation will be quantified and a decision aid will be developed and applied.\n\nThe main outcome measures are "Direct hospital cost", "Percentage of executed surgeries" and "Change in sciatic pain". In addition, data on health-related quality of life and resource utilization will be collected which will permit to estimate the incremental cost-effectiveness ratio (ICER), comparing incremental costs and quality adjusted life years (QALY).\n\nThe variables will be collected at the beginning, on the day of treatment and at 1, 3, 6, 12 and 24 months. The enrollment period will be 24 months. The follow-up period will be 24 months.\n\nThe results of the study will allow a better understanding of the value of ozone therapy in the management of patients on the waiting list for herniated disc surgery. In addition, it will contribute to the development of a more patient-centered health system.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Adults with symptomatic lumbar herniated disc in whom conservative medical management has failed and: 1) in whom discectomy or microdiscectomy is indicated, 2) have been included in surgery waiting list by the Neurosurgery Department, 3) who meet criteria for potential benefit with ozone therapy and 4) who accept participating in the study by answering/filling in the specific study questionnaires (wether they accept or not the ozone therapy).', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Diagnosed with a herniated and not calcified lumbar disc that presents as: not migrated protrusion and/or extrusion.\n* Evaluated and diagnosed by the Neurosurgery Department, having been chosen as an appropriate candidate for surgery consisting in discectomy or microdiscectomy, after meeting the following two criteria: 1) Sciatic pain, with a visual analogue scale (VAS) intensity ≥ 5, despite 6 weeks of conservative management, wether it exists lumbar pain or not and 2) Radiating pain that matches the MRI image showing one or more herniated discs (not to be considered those patients with two herniated discs and symptoms attributable to only one of the herniated discs).\n* Included in the surgery waiting list for a discectomy or microdiscectomy.\n* Patients who have signed and dated the study \'s specific informed consent.\n\nExclusion Criteria:\n\n* Patients who do not meet all the inclusion criteria.\n* Calcified and/or migrated herniated disc, and/or with a severe neurological deficits (cauda equine syndrome).\n* Herniated disc with surgical indication of laminectomy and/or arthrodesis (massive extrusion, sign of instability or other conditions under the neurosurgeon judgment).\n* Relevant clinical paresis that does not improve despite 6 weeks of full conservative management (patients with severe pain and mild paresis that only shows up in the physical exam are not to be excluded, but those who present with paresis as the main symptom -"clinically relevant"- must be).\n* Simultaneous symptomatic cervical or dorsal herniated discs.\n* Previous lumbar spine surgery.\n* Concomitant spine conditions that may be causing symptoms or have indication for surgery (such as fractures or tumors).\n* Known allergy to ozone.\n* Those who are uncapable to fill in the scales used to measure variables in the study, like the visual analogue scale (VAS), Roland-Morris and SF-12 questionnaires.\n* Those who are unable or do not wish to fulfill the study \'s protocol (answer questions to collect the data).'}, 'identificationModule': {'nctId': 'NCT03282695', 'acronym': 'O3HDCIRUGIA', 'briefTitle': 'Ozone Therapy in Patients on Waiting List for Surgery Due to Disc Herniation: Prospective, Post-authorization Study', 'organization': {'class': 'OTHER', 'fullName': 'Dr. Negrin University Hospital'}, 'officialTitle': 'Ozone Therapy in Patients on Waiting List for Surgery Due to Disc Herniation: Prospective, Post-authorization Study', 'orgStudyIdInfo': {'id': 'BCV-OZO-2016-01'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Surgery', 'description': 'Patients on waiting list for surgery (by discectomy/microdiscectomy) who reject ozone infiltration during waiting time.\n\nThese patients will receive standard pain treatment until the planned surgery.'}, {'label': 'Ozone', 'description': 'Patients on waiting list for surgery (by discectomy/microdiscectomy) who accept treatment by ozone infiltration during waiting time.\n\nThese patients will be treated primarily by ozone therapy: Infiltration of intradiscal O3/O2 + foraminal infiltration of O3/O2 + corticoid + anesthetic.\n\nThese patients will receive standard pain treatment until the planned surgery.'}]}, 'contactsLocationsModule': {'locations': [{'zip': '35019', 'city': 'Las Palmas de Gran Canaria', 'state': 'Las Palmas', 'country': 'Spain', 'facility': 'Dr. Negrin University Hospital', 'geoPoint': {'lat': 28.10178, 'lon': -15.41573}}], 'overallOfficials': [{'name': 'Bernardino Clavo, MD, PhD', 'role': 'STUDY_CHAIR', 'affiliation': 'Dr. Negrín University Hospital, Las Palmas, Spain'}, {'name': 'Pedro G. Serrano-Aguilar, MD, PhD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Servicio de Evaluación. Servicio Canario de Salud. Spain'}, {'name': 'Renata Linertová, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Fundación Canaria de Investigación Sanitaria (FUNCANIS)'}, {'name': 'Adam Szolna, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Dr. Negrín University Hospital, Las Palmas. Spain'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Bernardino Clavo, MD, PhD', 'class': 'OTHER'}, 'collaborators': [{'name': 'Servicio Canario de Salud', 'class': 'OTHER'}, {'name': 'Red de Investigación en Servicios de Salud en Enfermedades Crónicas', 'class': 'OTHER'}, {'name': 'Instituto de Salud Carlos III', 'class': 'OTHER_GOV'}, {'name': 'Colegio Oficial de Médicos de Las Palmas', 'class': 'UNKNOWN'}], 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'MD. PhD', 'investigatorFullName': 'Bernardino Clavo, MD, PhD', 'investigatorAffiliation': 'Dr. Negrin University Hospital'}}}}